45 results about "Natriuretic peptide" patented technology

The present disclosure relates to a polypeptide construct for targeted delivery of a payload, comprising a natriuretic peptide receptor (NPR-C) ligand. Also provided is a conjugate comprising; a polypeptide construct for targeted delivery of a payload to NPR-C expressing cells. Further provided are compositions comprising the construct or the conjugate, and kits comprising the construct and a crosslinker, and methods and uses of the same.

Provided are long-acting atrial natriuretic peptide (ANP) polypeptides that bind to natriuretic peptide receptors, such as NPR-A, thereby functioning as NPR-A agonists and that exhibit improved stability. The present invention provides atrial natriuretic peptides with specific structural features that result in polypeptides with sufficient activity at NPR-A and also possess a number of other beneficial attributes related to their potential development as therapeutic treatments, including improved solubility of the analogs in aqueous solution, improved chemical and physical formulation stability, an enhanced pharmacokinetic profile, and minimized potential immunogenicity.

The invention discloses a method for efficiently producing general type CAR-T. The general type CAR-T. Specifically, the invention provides a method for efficiently producing universal CAR-T. The method comprises the following steps: (s1) providing a T cell to be edited, and carrying out activated culture on the T cell to obtain an activated T cell; (s2) gene introduction: transfecting the activated T cell by using the LVV integrated with the CAR gene so as to obtain the T cell of which the genome is integrated with the CAR gene; (s3) gene knockout: transfecting the T cell obtained in (s2) by using LNP (Leukocyte Natriuretic Peptide) coated with Cas9mRNA (Cas9 Messenger Ribonucleic Acid) and sgRNA (Single Guide Ribonucleic Acid) so as to obtain a T cell in which the TCR gene and the CD7 gene are knocked out; and (s4) culturing the T cells obtained in the step (s3) so as to obtain the universal CAR-T. According to the method, the UCAR-T production cost can be remarkably reduced, the preparation period is shortened, and commercialization of shelf-type cell therapy is promoted.

The invention relates to the technical field of biological medicines, and provides a method for reducing acetonitrile residues in a recombinant human brain natriuretic peptide stock solution, which comprises the following steps: sequentially carrying out purification chromatography and ultrafiltration treatment on the human brain natriuretic peptide stock solution; during purification chromatography, a mobile phase comprises a phase A and a phase B; the phase A is a mixed solution of citric acid and sodium citrate; and the phase B is a mixed solution of citric acid, sodium citrate and sodium chloride. A chromatographic system is utilized, the recombinant human brain natriuretic peptide is adsorbed on a chromatographic medium under a specific mobile phase condition, then the chromatographic medium is switched to a proper B-phase buffer solution for elution, and in the process, acetonitrile is effectively separated and removed due to the adsorption characteristic difference between the acetonitrile and the recombinant human brain natriuretic peptide on the chromatographic medium. According to the technical scheme, the problem that the residual amount of acetonitrile in the recombinant human brain natriuretic peptide stock solution in related technologies is large is solved.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

Methods and materials for treating mammals having cardiovascular and / or metabolic disease are provided herein. For example, methods and materials for treating mammals having cardiovascular and / or metabolic disease by administering (a) an analog of a natriuretic peptide (NP), such as atrial natriuretic peptide (ANP) or dendroaspis natriuretic peptide (DNP), and (b) a glucagon-like peptide-1 (GLP-1) receptor / glucose-dependent insulinotropic polypeptide (GIP) receptor agonist are provided herein. The NP analogs used in the methods provided herein can be less than 20 amino acids in length and, in some cases, can have one or more variations in their ring portion (as compared to wild type ANP or DNP) that affect the potency of the analog in activating the particulate guanylyl cyclase (GC-A) receptor.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

[Solution] By using a naturally occurring substance, heart disease such as a myxomatous mitral valve disease is more effectively suppressed without impairing the health of small animals. [Effects] An agent contains, as main ingredients, 5 to 9 wt% of a pine bark dry extract derived from bark of pine trees grown on the southwestern coast of France under exposure to intense ultraviolet light and containing proanthocyanidin, and 5 to 9 wt% of a fermented sesame dry extract containing sesamin, one of the antioxidant lignans, the fermented sesame dry extract mainly containing sesame as a main raw material, and contains 79 to 87 wt% of an excipient such as starch or lactose, as a raw material, which makes a powder uniform, solidifies a tablet, and prevents quality deterioration due to moisture absorption or the like, such as starch or lactose.

A method for detecting hBNP, or a precursor or a degradation product of the same, in a sample according to one aspect of the present invention comprises a step for detecting, by a latex coagulating method, hBNP, or a precursor or a degradation product of the same, in the sample by using: a monoclonal antibody that recognizes an amino acid region at positions 17-24 in the amino acid sequence indicated by SEQ ID NO. 1, or an antigen binding fragment of the monoclonal antibody; and a monoclonal antibody that recognizes an amino acid region at positons 5-13 in the amino acid sequence indicated by SEQ ID NO. 1, or an antigen binding fragment of the monoclonal antibody. The precursor of hBNP is hproBNP, and the degradation product of hBNP is a degradation product including an amino acid region at positions 5-24 in the amino acid sequence indicated by SEQ ID NO. 1. According to the present invention, it is possible to detect hBNP by using a latex coagulating method while suppressing effects caused by steric hindrance of antibody-immobilized latex particles and degradation of terminals of hBNP.

The invention relates to a traditional Chinese medicine composition for treating ischemic heart failure and a preparation method thereof, and belongs to the field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-15 parts of cassia twig, 5-15 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 6-12 parts of rhizoma zingiberis, 5-15 parts of acanthopanax, 10-30 parts of fructus polygoni orientalis, 3-9 parts of verbena, 6-12 parts of dogwood and 3-9 parts of honey-fried licorice root. The composition can remarkably reduce the level of N-terminal proB-type natriuretic peptide, remarkably improve pathological changes of heart tissues of model rats, regulate and control the heart functions of the model rats, improve the systolic function of the heart, relieve expression of inflammatory factors such as interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha of the rats and improve the anti-inflammatory effect of the rats. The action mechanism of the compound relates to a plurality of pathways such as extracellular matrix receptor interaction, a chemotactic factor signal pathway, a relaxin signal pathway, a cyclic adenosine monophosphate signal pathway, a nuclear factor-kB signal pathway, fatty acid metabolism and a Toll-like receptor signal pathway, and the compound is an effective medicament for treating ischemic heart failure.

Methods and materials for treating or preventing cardiotoxicity and / or hypertension induced by one or more anti-cancer agents (e.g., tyrosine kinase inhibitor (TKI) -induced cardiotoxicity (e.g., sunitinib-induced cardiotoxicity) and / or TKI-induced hypertension (e.g., sunitinib-induced hypertension)) are provided herein. For example, provided herein are methods for using polypeptides (e.g., chimeric polypeptides) that include (a) one or more natriuretic peptides and (b) one or more angiotensin 1-7 (ANG1-7) polypeptides to treat or prevent cardiotoxicity and / or hypertension induced by one or more anti-cancer agents.

To provide a method of measuring an N-terminal fragment of a human brain natriuretic peptide precursor, which reduces the effect of a duration from collection of a sample till detection on separation property of a complex, and to provide a measurement kit for implementing the above method.SOLUTION: A method of measuring a human brain natriuretic peptide precursor N-terminal fragment in a sample is provided, the method comprising separating a complex containing the human brain natriuretic peptide precursor N-terminal fragment and a substance binding to the human brain natriuretic peptide precursor N-terminal fragment in the presence of a polyanionic polymer, and measuring the complex, where the concentration of the polyanionic polymer in a separation medium is 5.1% (w / v) or greater.SELECTED DRAWING: None

A synthetic protein comprising: an N-terminal collagen-binding domain (CBD); a C-terminal C-type natriuretic peptide domain (CNP); and optionally, a spacer linking the CBD and the CNP.

Provided is a chimeric natriuretic peptide or a variant thereof. The chimeric natriuretic peptide comprises or consists of an N-terminal extension fragment, a cyclic fragment and a C-terminal extension fragment from the N-terminus to the C-terminus. The N-terminal extension fragment is truncated from an N-terminal linear region of DNP or an N-terminal linear region of ANP; the cyclic fragment is formed by truncating an N-terminal linear region and a C-terminal linear region of BNP while retaining a cyclic region thereof; and the C-terminal extension fragment is truncated from a C-terminal linear region of DNP. The chimeric natriuretic peptide has enhanced cGMP activation ability. Further provided are a fusion protein, nucleic acid molecule, recombinant vector, host cell, immunoconjugate and pharmaceutical composition of the chimeric natriuretic peptide or the variant thereof, and the related use thereof.

To provide long-acting atrial natriuretic peptide (ANP) polypeptides that bind to natriuretic peptide receptors such as NPR-A, thereby function as NPR-A agonists, and exhibit improved stability.SOLUTION: Provided are atrial natriuretic peptides having specific structural features. The structural features also result in polypeptides having sufficient activity at NPR-A and also result in polypeptides having many other beneficial attributes associated with their developability as therapeutic treatments, including improved solubility of analogs in aqueous solution, improved chemical and physical formulation stability, extended pharmacokinetic profiles, and minimization of immunogenicity potential.SELECTED DRAWING: None

The invention discloses a fluorescent / photo-thermal dual-mode imaging composite nanoprobe for detecting N-terminal B-type pro-natriuretic peptide as well as preparation and application of the fluorescent / photo-thermal dual-mode imaging composite nanoprobe, and relates to the technical field of medicine and biochemistry. According to the composite nanoprobe, a fluorescent dye Cy7 modified nucleic acid aptamer is loaded on the surface of AuAgPt NPs, fluorescence signal regulation and control are achieved through nanometal surface energy transfer and an inner filter effect, the concentration of N-terminal B-type pronatriuretic peptide can be quantitatively and sensitively analyzed, and the detection limit is as low as 0.13 pg / mL. The probe integrates near-infrared fluorescence / photo-thermal dual-mode imaging to realize dynamic monitoring of N-terminal B-type pro-natriuretic peptide in a body organ. The composite nanoprobe can be used for in-vitro accurate and high-sensitivity detection of the N-terminal B-type natriuretic peptide, provides a favorable method for early diagnosis of heart failure, can also be used for in-vivo dynamic monitoring of the N-terminal B-type natriuretic peptide, and provides a promising new tool for pathological research and individualized diagnosis and treatment of diseases such as heart failure.

To provide a drug delivery system for treating glaucoma or related conditions.SOLUTION: Provided is a drug delivery system comprising (1) a prostaglandin, a CNTF compound, a TNF-α / TNFR inhibitor, a FAS or FASL inhibitor, or any combination thereof, and (2) a sustained delivery component.SELECTED DRAWING: None

The present disclosure relates, in general, to methods of treating short stature disorders in a subject who is non-responsive to growth hormone therapy using variants of C-type natriuretic peptide (CNP).

Provided are an antibody that binds specifically to N-terminal pro-B-type natriuretic peptide (NT-proBNP) and use thereof. An antibody or antigen-binding fragment thereof, which binds specifically to an epitope of NT-proBNP including the amino acid sequence of HXLGXXX (SEQ ID NO: 2), may detect NT-proBNP, which is a heart disease biomarker, and heart disease can also be effectively diagnosed by using the same.

The invention relates to a myocardial injury risk assessment decision-making method and system based on multi-model stacking deep learning, and the method comprises the steps: obtaining the data of three physiological indexes of cardiac troponin I (cTnI), N-terminal B-type natriuretic peptide precursor (NT-proBNP) and creatine kinase-MB) of a target population, carrying out Z-Score standardization preprocessing, and carrying out the Z-Score standardization preprocessing; and inputting the standard feature vector into a multi-layer perceptron (MLP) model and an extreme gradient boost (XGBoost) model in parallel. The MLP model is used for extracting nonlinear abstract features, and the XGBoost model is used for capturing piecewise linear discrimination boundaries among the features. Then, prediction probabilities output by the two models are used as meta-features to be input into a logistic regression meta-learner, and a final risk assessment probability is calculated through weighted fusion. According to the method, a stacked ensemble learning mechanism is adopted, the advantages of a heterogeneous model are effectively fused, and the risk assessment accuracy and stability under the conditions of small samples and few indexes are remarkably improved.

To provide longer-acting forms of C-type natriuretic peptide (CNP) and analogs thereof in more convenient forms for the treatment of various conditions and diseases, such as dwarfism and achondroplasia, which allow maintenance of therapeutic levels of peptide between administrations so as to provide therapeutic peptide levels for a sufficient time in a daily administration schedule without the need for overdosing.SOLUTION: Provided herein are extended release hydrogel conjugates of c-natriuretic peptides, methods of preparation thereof, and methods of use thereof.SELECTED DRAWING: None

The present application relates to a kind of kit and detection method for detecting heart failure marker, belong to heart failure marker detection technical field.The kit includes basic buffer A (pH=7.4, containing 0.5mol / L NaCl and 10mmol / L Tris aqueous solution), basic buffer B (pH=7.4, containing 3mol / L NaCl and 10mmol / L Tris aqueous solution) and washing liquid (0.5~3mol / L alkali metal chloride).The detection method disclosed in the present application mainly forms ion gradient direction on the two sides of the electrochemical device with nano-pore respectively by basic buffer A and basic buffer B, releases the electrochemical signal characteristics of large sodium peptide, compares the sample characteristic map of serum sample with the sample characteristic map of standard B-type natriuretic peptide by the amplitude of current signal and current block time characteristic analysis, detects and quantifies B-type natriuretic peptide in serum to-be-detected object, and its detection limit is as low as 767.92fmol / L.

To provide CNP variants and conjugates thereof.SOLUTION: The present disclosure relates, in general, to stable variants of C-type natriuretic peptide (CNP) and uses thereof for treating bone-related disorders. The present disclosure relates to novel variants of C-type natriuretic peptide (CNP) having increased circulating half-life and stability in aqueous media, pharmaceutical compositions comprising such CNP variants, and methods of using such CNP variants to treat disorders responsive to CNP, including but not limited to bone-related disorders such as achondroplasia.SELECTED DRAWING: Figure 2A

The present invention relates to a method for selecting a patient suffering from a stroke for reperfusion therapy, based on determining the levels of retinol binding protein 4 (RBP4) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The present invention also relates to a method for differentiating between ischemic stroke and hemorrhagic stroke, and to a kit comprising reagents for performing said methods.

The present disclosure, relates, in general, to stable variants of C-type natriuretic peptide (CNR) and uses thereof to treat bone-related disorders.

Provided herein are sustained-release hydrogel conjugates of c-natriuretic peptide, methods for making same, and methods for using same.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.

A method, system, and medium for dynamically controlling infusion drip rate based on patient physiological parameters include: acquiring real-time physiological parameter data, medical history data, and drug attribute data of the patient; real-time physiological parameter data including glomerular filtration rate and B-type natriuretic peptide concentration; obtaining a safe drip rate range based on one or more of the real-time physiological parameter data, medical history data, and drug attribute data according to a preset rule base; calculating a recommended drip rate based on a machine learning model and a standard drip rate; obtaining a preset drip rate threshold range, and generating and outputting a first drip rate control command based on the recommended drip rate, the safe drip rate range, and the preset drip rate threshold range; monitoring the actual drip rate in real time and calculating the error value between the actual drip rate and the recommended drip rate; and dynamically adjusting the first drip rate control command based on the error value using a closed-loop control algorithm to generate and output a second drip rate control command.

The present invention relates to a kit for selecting a patient for reperfusion therapy and its preparation and use based on determining the level of N-terminal fragment of B-type natriuretic peptide (NT-proBNP) and the level of d-dimer in an isolated sample of said patient. The invention also relates to a method for distinguishing cerebral arterial thrombosis from cerebral hemorrhagic thrombosis, and relates to a kit containing a reagent for executing the method.

The invention discloses two B-type natriuretic peptide antibodies and application thereof, and relates to the field of antibodies. The two antibodies disclosed by the invention comprise a heavy chain complementarity determining region and a light chain complementarity determining region, provide an important raw material source for detection of B-type natriuretic peptide, and have good affinity or activity.